Supplemental Materials
Liu Z, Myers LC. ‘Mediator Tail Module is Required for Tac1 Activated *CDR1* Expression and Azole Resistance in *Candida albicans*.’

Contents:

Fig. S1



Fig. S1 Analysis of Tac1 occupancy at the *CDR1* and *CDR2* promoters using additional primer pairs

Anti-Flag ChIP products obtained from strains expressing 6His3Flag tagged Tac1 (yLM485) or untagged native Tac1 (DSY2937-35), in the absence or presence of fluphenazine (10 µg/mL; 15 minutes), were analyzed for Tac1 occupancy profile across the *CDR1* and *CDR2* promoters. Recovery rate (% Input) of DNA fragments containing '1-DRE' amplicon in the ChIP product obtained from uninduced culture of the strain untagged Tac1 (DSY2937-35) was set to '1' to calculate relative recovery at additional regions. Columns representing the recovery at the two DREs were marked black.

Fig. S2



Fig. S2 Induction of Tac1 target genes in *snf2* deletion strains

RT-qPCR analysis of *CDR2* **(A)**, *RTA3* **(B)** and *CDR1* **(C)** induction in *SNF2+/+* ('+') strains bearing individual *TAC1* variants (WT (DSY2937-35), *T225A* (ACY67), *A736V* (ACY13) or *G980E* (ACY71)) and their *snf2* deletion derivatives ('*Δ*'; yLM472, yLM474, yLM476 and yLM478 respectively) were treated with 10 µg/mL fluphenazine or vehicle for 15 minutes as indicated. *TEF1* abundance was used as internal reference. Basal expression of each gene measured from the untreated *SNF2/TAC1* wild type strain (DSY2937-35) was set to '1' to calculate relative gene expression.

Fig. S3



Fig. S3 Time Course analysis of SDS-PAGE mobility shift and corresponding *CDR1* and *CDR2* expression

(A-B) RT-qPCR analysis of *CDR1* and *CDR2* expression on RNA extracted from the samples collected in **Fig. 8A**. Basal expression of each gene, measured before any treatment, was set to '1'. **(C)** and **(D)** RT-qPCR analysis of *CDR1* and *CDR2* expression in a 6His3Flag tagged wild type Tac1 expressing strain (yLM485) grown in the presence of differing concentrations of fluphenazine for the indicated period of time. **(E)** Immunoblot of Tac1 mobility shift in lysates prepared from samples collected for the analysis in **(C)** and **(D)**. Whole cell lysates were resolved on 6% SDS-PAGE gel and probed with an anti-Flag antibody. Coomassie blue staining (CBS) was used as the loading control.

Fig. S4



Fig. S4 A Tac1 C43Y mutant protein is unable to bind DNA, activate transcription of *CDR1* or *CDR2*, or undergo a phosphorylation mobility shift.
(A) Anti-Flag ChIP analysis of Tac1^{C43Y} occupancy at the *CDR1* and *CDR2* promoters in strains expressing 6His3Flag (HF) tagged wild type Tac1(‘*HF-WT*’; yLM485) or Tac1^{C43Y} (‘*HF-C43Y*’; yLM537). Recovery rate (% Input) of DNA fragments containing the ‘1-DRE’ amplicon in the ChIP product obtained from a strain expressing untagged native Tac1 (‘WT’; DSY2937-35) was set to ‘1’ to calculate relative recovery at additional regions. **(B-C)** RT-qPCR analyses of *CDR1* **(B)** and *CDR2* **(C)** expression in strains expressing 6His3Flag tagged wild type Tac1 (‘WT’; yLM485) or Tac1^{C43Y} (‘C43Y’; yLM537) treated with 10 µg/mL fluphenazine for the indicated period of time. *CDR1* and *CDR2* expression levels in the 6His3Flag-Tac1^{WT} strain (yLM485) were set to ‘1’ individually. **(D)** Immunoblot analysis of the Tac1^{C43Y} phosphorylation shift in the lysates prepared from the samples collected for the analysis in **(B)** and **(C)** by using an anti-Flag antibody. The samples were resolved by 6% SDS-PAGE. Coomassie blue staining (CBS) was used as the loading control. **(E-F)** RT-qPCR analyses of *CDR1* **(E)** and *CDR2* **(F)** expression in strains expressing 6His3Flag tagged Tac1^{WT} (yLM485), Tac1^{R693K} (yLM532) or Tac1$^{R693K/C43Y}$ (yLM538). **(G)** Immunoblot analysis of Tac1 in lysates from strains expressing 6His3Flag tagged Tac1^{R693K} (yLM532) or Tac1$^{R693K/C43Y}$ (yLM538) using an anti-Flag antibody. Samples were resolved by 6% SDS-PAGE.

Coomassie blue staining (CBS) was used as the loading control. Panels originate from different lanes of the same exposure of the same blot and gel.

Fig. S5



Fig. S5 Expression of Tac1 target genes, induced by estradiol treatment or different concentration of fluphenazine, in *ssn3* mutant strains

(A-B) RT-qPCR analyses of *CDR1* **(A)** and *CDR2* **(B)** induction in *SSN3*+/+ and *ssn3Δ/Δ* strains expressing wild type Tac1 (DSY2937-35 and yLM236, respectively) by different concentrations of fluphenazine. The expression level of each gene in the untreated *SSN3*+/+ strain (DSY2937-35) was set to '1'. **(C-E)** RT-qPCR analysis of *CDR1* **(C)**, *CDR2* **(D)** and *RTA3* **(E)** induction in an *ssn3Δ/Δ* strain expressing wild type Tac1 (yLM236) by 10 μg/mL estradiol (EST). Parallel analysis of estradiol induction in a wild type ('WT'; DSY2937-35) and a *med3Δ/Δ* mutant (yLM232) strain are presented for comparison. The expression level of each gene measured in the untreated wild type strain (DSY2937-35) was set to '1'. **(F-G)** RT-qPCR analysis of estradiol induced *CDR1* **(F)** and *CDR2* **(G)** expression in an *ssn3Δ/Δ* null strain (yLM265) complemented by either wild type *SSN3*^{WT} (yLM279) or a kinase dead allele *SSN3*^{D325A} (yLM276). The *CDR1* and *CDR2* expression levels in the *SSN3*^{WT} complementary strain culture (yLM279) collected before induction were individually set to '1'.

Table S1 RT-qPCR analysis of *CDR1* expression activated by *TAC1*^{GOF} mutants and xenobiotic exposure in wild type and *med3* deletion strains.

***TAC1* allele**	**Relative *CDR1* Expression Level [a] (mean ± SD)**					
	MED3+/+		***med3Δ/Δ***			
	YPD	**+FNZ**	**YPD**	**Fold Change[b]**	**+FNZ**	**Fold Change[c]**
tac1Δ/Δ	*1.32±0.01*[d]	*1.55±0.05*	ND[e]	**ND**	ND	**ND**
WT	*1±0.07*	*7.18±0.12*	0.59±0.02	**0.59**	1.34±0.08	**0.19**
T225A	*2.91±0.06*	*7.28±0.06*	*1.32±0.03*	**0.45**	*1.29±0.01*	**0.18**
A736V	*4.23±0.12*	*10.52±0.35*	*1.60±0.12*	**0.38**	*1.67±0.01*	**0.16**
G980E	*5.46±0.11*	*10.87±0.07*	*2.05±0.12*	**0.38**	*2.02±0.16*	**0.19**
E461K	2.32±0.19	5.90±0.3	1.23±0.04	**0.53**	1.07±0.07	**0.18**
ΔM677	3.26±0.22	6.81±0.05	1.21±0.03	**0.37**	1.11±0.01	**0.16**
N972D	4.54±0.06	7.01±0.03	1.30±0.11	**0.29**	1.05±0.01	**0.15**
Δ962-969	3.86±0.07	6.94±0.14	1.19±0.07	**0.31**	1.13±0.03	**0.16**
N977D	3.84±0.12	6.28±0.07	1.38±0.04	**0.36**	1.13±0.05	**0.18**

[a] The *CDR1+/+ MED3+/+* and *CDR1+/+ med3Δ/Δ* strains tested in **Table 1** and a *CDR1+/+ MED3+/+ tac1Δ/Δ* strain (DSY2906), were compared for *CDR1* expression under fluphenazine treated ('+FNZ'; 20 µg/mL for 30 minutes) and non-treated ('YPD') conditions. The *CDR1* level in the non-treated *CDR1+/+ MED3+/+ TAC1*^{WT} strain (DSY2937-35) was set to '1'.

[b] *CDR1* mRNA level fold change caused by *med3* deletion under normal growth conditions

[c] *CDR1* mRNA level fold change caused by *med3* deletion under FNZ inducing conditions

[d] Data in *italics* is also shown in a bar graph in **Fig. 1A**.

[e] ND*:* Not determined

Table S2. RT-qPCR analysis of *CDR2* expression activated by *TAC1*^{GOF} mutants in wild type and *med3* deletion strains

TAC1	**Relative Expression Level of *CDR2* in YPD medium** [a]		
allele	***MED3+/+***	***med3Δ/Δ***	**Fold Change**
WT	*1±0.08* [b]	1.61±0.18	**1.61**
T225A	*87.32±7.88*	*103.83±2.83*	**1.50**
A736V	*155.90±3.03*	*135.20±2.12*	**0.87**
G980E	*356.51±2.68*	*370.56±21.2*	**1.04**
WT [c]	1±0.04	1.30±0.02	**1.30**
E461K [c]	38.61±2.47	55.87±1.30	**1.45**
ΔM677 [c]	55.81±1.35	59.18±2.75	**1.06**
N972D [c]	98.81±0.38	95.83±2.16	**0.97**
Δ962-969 [c]	65.79±0.84	68.09±2.48	**1.03**
N977D [c]	97.84±1.83	97.62±2.66	**1.00**

[a] The *CDR1+/+ MED3+/+* and *CDR1+/+ med3Δ/Δ* strains tested in **Table 1** were compared for *CDR2* expression under normal growth conditions (YPD).

[b] Data in *italics* presents the first group of assays and is also shown in a bar graph form in **Fig. 1C**.

[c] The second group of assays (denoted with a '[c]') were performed separately from the first (data in *italics*). Basal *CDR2* levels measured from the *TAC1*^{WT} *MED3+/+* strain cultures were individually set to '1' to calculate and compare *CDR2* relative expression between strains within each group.

Table S3 Fluconazole MIC in *med3Δ/Δ cdr2Δ/Δ* strains bearing *TAC1*^{GOF} mutations

TAC1 **allele**	**Fluconazole MIC (µg/mL)** [a,b]	
	med3Δ/Δ ***CDR2+/+***	***med3Δ/Δ*** ***cdr2Δ/Δ***
WT	**0.5-0.75** (yLM232)	**0.5-0.75** (yLM523)
A736V	**6-8** (yLM234)	**6-8** (yLM525)
ΔM677	**4** (yLM504)	**4** (yLM600)
N972D	**4** (yLM495)	**4** (yLM527)
N977D	**4-6** (yLM498)	**4-6** (yLM529)

[a] Fluconazole MIC was measured by E-test at 30°C on YPD plate. Plates were incubated for 36 hours before read-out. Intermediate values, between scale marks, are presented as intervals.

[b] Exact strain used for each MIC measurement listed in parentheses.

Table S4 *C. albicans* strains used in this study

Strain Name	Parental strain	Constructs integrated	Genotype	Ref.
DSY2906 (yLM166)	-		*tac1-1Δ::hisG/ tac1-2Δ::hisG*	(1)
DSY2937-35 (yLM167)	-		*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1**/URA3*	(2)
yLM208	DSY2937-35 (yLM167)	*pSFS2-MED3KO*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1**/URA3 **med3Δ::FRT**/MED3*	This study #
yLM232	yLM208	*pSFS2-MED3KO*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1**/URA3 **med3Δ::FRT/ med3Δ::FRT***	This study #
yLM216	DSY2937-35 (yLM167)	*pSFS2- SSN3KO*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1**/URA3 **ssn3Δ::FRT**/SSN3*	This study
yLM236	yLM216	*pSFS2- SSN3KO*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1**/URA3 **ssn3Δ::FRT/ssn3Δ::FRT***	This study
yLM225	DSY2937-35 (yLM167)	*pSFS2-MED15KO*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1**/URA3 **med15Δ::FRT**/MED15*	This study
yLM240	yLM225	*pSFS2-MED15KO*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1**/URA3 **med15Δ::FRT/med15Δ::FRT***	This study
ACY67 (yLM168)	-		*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-T225A**/URA3*	(3)
yLM210	ACY67 (yLM168)	*pSFS2-MED3KO*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-T225A**/URA3 **med3Δ::FRT**/MED3*	This study
yLM233	yLM210	*pSFS2-MED3KO*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-T225A**/URA3 **med3Δ::FRT/ med3Δ::FRT***	This study
yLM218	ACY67 (yLM168)	*pSFS2- SSN3KO*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-T225A**/URA3 **ssn3Δ::FRT**/SSN3*	This study
yLM237	yLM218	*pSFS2- SSN3KO*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-T225A**/URA3 **ssn3Δ::FRT/ssn3Δ::FRT***	This study
yLM226	ACY67 (yLM168)	*pSFS2-MED15KO*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-T225A**/URA3 **med15Δ::FRT**/MED15*	This study
yLM241	yLM226	*pSFS2-MED15KO*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-T225A**/URA3 **med15Δ::FRT/med15Δ::FRT***	This study
ACY13 (yLM169)	-		*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-A736V**/URA3*	(3)
yLM212	ACY13 (yLM169)	*pSFS2-MED3KO*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-A736V**/URA3 **med3Δ::FRT**/MED3*	This study
yLM234	yLM212	*pSFS2-MED3KO*	*tac1-1Δ::hisG/ tac1-2Δ::hisG*	This study

			*LEU2::**TAC1-1-A736V**/URA3 **med3Δ::FRT/ med3Δ::FRT***	
yLM220	ACY13 (yLM169)	*pSFS2-SSN3KO*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-A736V**/URA3 **ssn3Δ::FRT/**SSN3*	This study
yLM238	yLM220	*pSFS2-SSN3KO*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-A736V**/URA3 **ssn3Δ::FRT/ssn3Δ::FRT***	This study
yLM229	ACY13 (yLM169)	*pSFS2-MED15KO*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-A736V**/URA3 **med15Δ::FRT/**MED15*	This study
yLM242	yLM229	*pSFS2-MED15KO*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-A736V**/URA3 **med15Δ::FRT/med15Δ::FRT***	This study
ACY71 (yLM170)	-		*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-G980E**/URA3*	(3)
yLM214	ACY71 (yLM170)	*pSFS2-MED3KO*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-G980E**/URA3 **med3Δ::FRT/**MED3*	This study
yLM235	yLM214	*pSFS2-MED3KO*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-G980E/**URA3 **med3Δ::FRT/ med3Δ::FRT***	This study
yLM222	ACY71 (yLM170)	*pSFS2-SSN3KO*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-G980E**/URA3 **ssn3Δ::FRT/**SSN3*	This study
yLM239	yLM222	*pSFS2-SSN3KO*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-G980E**/URA3 **ssn3Δ::FRT/ssn3Δ::FRT***	This study
yLM230	ACY71 (yLM170)	*pSFS2-MED15KO*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-G980E**/URA3 **med15Δ::FRT/**MED15*	This study
yLM243	yLM230	*pSFS2-MED15KO*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-G980E**/URA3 **med15Δ::FRT/med15Δ::FRT***	This study
yLM490	DSY2906 (yLM166)	*TAC1Inte E461K*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-E461K**/URA3*	This study
yLM491	yLM490	*pSFS2-MED3KO*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-E461K**/URA3 **med3Δ::FRT/**MED3*	This study
yLM492	yLM491	*pSFS2-MED3KO*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-E461K/**URA3 **med3Δ::FRT/med3Δ::FRT***	This study
yLM493	DSY2906 (yLM166)	*TAC1Inte N972D*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-N972D**/URA3*	This study
yLM494	yLM493	*pSFS2-MED3KO*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-N972D**/URA3 **med3Δ::FRT/**MED3*	This study
yLM495	yLM494	*pSFS2-MED3KO*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-N972D**/URA3*	This study

			med3Δ::FRT/med3Δ::FRT	
yLM496	DSY2906 (yLM166)	*TAC1Inte N977D*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-N977D**/URA3*	This study
yLM497	yLM496	*pSFS2-MED3KO*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-N977D**/URA3 **med3Δ::FRT/**MED3*	This study
yLM498	yLM497	*pSFS2-MED3KO*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-N977D**/URA3 **med3Δ::FRT/med3Δ::FRT***	This study
yLM499	DSY2906 (yLM166)	*TAC1Inte Δ962-969*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-Δ962-969**/URA3*	This study
yLM500	yLM499	*pSFS2-MED3KO*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-Δ962-969**/URA3 **med3Δ::FRT/**MED3*	This study
yLM501	yLM500	*pSFS2-MED3KO*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-Δ962-969**/URA3 **med3Δ::FRT/med3Δ::FRT***	This study
yLM502	DSY2906 (yLM166)	*TAC1Inte ΔM677*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-ΔM677**/URA3*	This study
yLM503	yLM502	*pSFS2-MED3KO*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-ΔM677**/URA3 **med3Δ::FRT/**MED3*	This study
yLM504	yLM503	*pSFS2-MED3KO*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-ΔM677**/URA3 **med3Δ::FRT/med3Δ::FRT***	This study
yLM505	DSY2937-35 (yLM167)		*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1**/URA3 CDR1::**CDR1-3HA**/CDR1*	This study
yLM506	yLM232		*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1**/URA3 **med3Δ::FRT/ med3Δ::FRT** CDR1::**CDR1-3HA**/CDR1*	This study
yLM507	ACY67 (yLM168)		*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-T225A**/URA3 CDR1::**CDR1-3HA**/CDR1*	This study
yLM508	yLM233		*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-T225A**/URA3 **med3Δ::FRT/ med3Δ::FRT** CDR1::**CDR1-3HA**/CDR1*	This study
yLM509	ACY13 (yLM169)		*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-A736V**/URA3 CDR1::**CDR1-3HA**/CDR1*	This study
yLM510	yLM234		*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-A736V**/URA3 **med3Δ::FRT/ med3Δ::FRT** CDR1::**CDR1-3HA**/CDR1*	This study
yLM511	ACY71 (yLM170)		*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-G980E**/URA3 CDR1::**CDR1-3HA**/CDR1*	This study
yLM512	yLM235		*tac1-1Δ::hisG/ tac1-2Δ::hisG*	This study

			*LEU2::**TAC1-1-G980E**/URA3 **med3Δ::FRT/ med3Δ::FRT** CDR1::**CDR1-3HA**/CDR1*	
yLM513	yLM502		*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-ΔM677**/URA3 CDR1::**CDR1-3HA**/CDR1*	This study
yLM514	yLM490		*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-E461K**/URA3 CDR1::**CDR1-3HA**/CDR1*	This study
yLM515	yLM492		*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-E461K/URA3 med3Δ::FRT/med3Δ::FRT** CDR1::**CDR1-3HA**/CDR1*	This study
yLM516	yLM493		*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-N972D**/URA3 CDR1::**CDR1-3HA**/CDR1*	This study
yLM517	yLM495		*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-N972D**/URA3 **med3Δ::FRT/med3Δ::FRT** CDR1::**CDR1-3HA**/CDR1*	This study
yLM518	yLM496		*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-N977D**/URA3 CDR1::**CDR1-3HA**/CDR1*	This study
yLM519	yLM498		*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-N977D**/URA3 **med3Δ::FRT/med3Δ::FRT** CDR1::**CDR1-3HA**/CDR1*	This study
yLM520	yLM499		*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-Δ962-969**/URA3 CDR1::**CDR1-3HA**/CDR1*	This study
yLM521	yLM501		*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-Δ962-969**/URA3 **med3Δ::FRT/med3Δ::FRT** CDR1::**CDR1-3HA**/CDR1*	This study
yLM522	yLM208	*pSFS2-CDR2KO* **(two rounds)**	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1**/URA3 **med3Δ::FRT**/MED3 **cdr2Δ::FRT/ cdr2Δ::FRT***	This study
yLM523	yLM522	*pSFS2-MED3KO*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1**/URA3 **med3Δ::FRT/med3Δ::FRT cdr2Δ::FRT/cdr2Δ::FRT***	This study
yLM524	yLM212	*pSFS2-CDR2KO* **(two rounds)**	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-A736V**/URA3 **med3Δ::FRT**/MED3 **cdr2Δ::FRT/ cdr2Δ::FRT***	This study
yLM525	yLM524	*pSFS2-MED3KO*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-A736V**/URA3 **med3Δ::FRT/med3Δ::FRT***	This study

			cdr2Δ::FRT/cdr2Δ::FRT	
yLM526	yLM494	*pSFS2-CDR2KO* **(two rounds)**	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::* ***TAC1-1-N972D*** */URA3* ***med3Δ::FRT***/*MED3* ***cdr2Δ::FRT/cdr2Δ::FRT***	This study
yLM527	yLM526	*pSFS2-MED3KO*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::* ***TAC1-1-N972D***/*URA3* ***med3Δ::FRT/med3Δ::FRT*** ***cdr2Δ::FRT/cdr2Δ::FRT***	This study
yLM528	yLM497	*pSFS2-CDR2KO* **(two rounds)**	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::* ***TAC1-1-N977D*** */URA3* ***med3Δ::FRT***/*MED3* ***cdr2Δ::FRT/ cdr2Δ::FRT***	This study
yLM529	yLM528	*pSFS2-MED3KO*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::* ***TAC1-1-N977D***/*URA3* ***med3Δ::FRT/med3Δ::FRT*** ***cdr2Δ::FRT/cdr2Δ::FRT***	This study
SN152 (AZC22)			*arg4/arg4 leu2/leu2 his1 /his1 URA3/ura3 ::imm434 IRO1/iro1 ::imm434*	(4)
AZC32			*arg4/arg4 leu2/leu2 his1 /his1 URA3/ura3::imm434 IRO1/iro1::imm434* ***med5Δ::HIS1/med5Δ::LEU2***	(5)
AZC34			*arg4/arg4 leu2/leu2 his1 /his1 URA3/ura3::imm434 IRO1/iro1::imm434* ***med16Δ::HIS1/med16Δ::LEU2***	(5)
AZC42			*arg4/arg4 leu2/leu2 his1 /his1 URA3/ura3::imm434 IRO1/iro1::imm434* ***med9Δ::HIS1/med9Δ::LEU2***	(5)
AZC44			*arg4/arg4 leu2/leu2 his1 /his1 URA3/ura3::imm434 IRO1/iro1::imm434* ***med20Δ::HIS1/med20Δ::LEU2***	(5)
AZC46			*arg4/arg4 leu2/leu2 his1 /his1 URA3/ura3::imm434 IRO1/iro1::imm434* ***med1Δ::HIS1/med1Δ::LEU2***	(5)
AZC51 (yLM95)			*arg4/arg4 leu2/leu2 his1 /his1 URA3/ura3::imm434 IRO1/iro1::imm434* ***med3Δ::HIS1/med3Δ::LEU2***	(6)
cTTR01			*arg4/arg4 leu2/leu2 his1 /his1 URA3/ura3::imm434 IRO1/iro1::imm434* ***med15Δ::HIS1/med15Δ::LEU2***	(5)
AZC52			*arg4/arg4 leu2/leu2 his1 /his1 URA3/ura3::imm434 IRO1/iro1::imm434* ***med12Δ::HIS1/med12Δ::LEU2***	(5)
yLM485	DSY2906 (yLM166)	*TAC1InteHF-WT*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::* **P_{TAC1}*-6HIS3FLAG-TAC1-1*** */URA3*	This study #
yLM530	DSY2906 (yLM166)	*TAC1InteHF-WT*$_{OE}$	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::* **P_{ACT1}*-6HIS3FLAG-TAC1-1*** */URA3*	This study
yLM531	DSY2906 (yLM166)	*TAC1InteHF-A736V*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::* **P_{TAC1}*-6HIS3FLAG-TAC1-1-A736V*** */URA3*	This study
yLM532	DSY2906 (yLM166)	*TAC1InteHF-R693K*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::* **P_{TAC1}*-6HIS3FLAG-TAC1-1-R693K*** */URA3*	This study
yLM533	DSY2906 (yLM166)	*TAC1InteHF-ΔM677*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::* **P_{TAC1}*-6HIS3FLAG-TAC1-1-ΔM677*** */URA3*	This study

yLM534	DSY2906 (yLM166)	*TAC1InteHF-N972D*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::***P_{TAC1}-6HIS3FLAG-TAC1-1-N972D***/URA3*	This study
yLM535	DSY2906 (yLM166)	*TAC1InteHF-Δ962-969*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::***P_{TAC1}-6HIS3FLAG-TAC1-1-Δ962-969***/URA3*	This study
yLM536*	DSY2906 (yLM166)	*TAC1InteHF-N977D*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::***P_{TAC1}-6HIS3FLAG-TAC1-1-N977D***/URA3*	This study
yLM537	DSY2906 (yLM166)	*TAC1InteHF-C43Y*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::***P_{TAC1}-6HIS3FLAG-TAC1-1-C43Y/***URA3*	This study
yLM538	DSY2906 (yLM166)	*TAC1InteHF-R693K/C43Y*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::***P_{TAC1}-6HIS3FLAG-TAC1-1-R693K-C43Y***/URA3*	This study
yLM539	DSY2906 (yLM166)	*TAC1InteHF-TAC1ΔTAD*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::***P_{TAC1}-6HIS3FLAG-TAC1-1-ΔTAD(aa1-845)***/URA3*	This study
yLM540	DSY2906 (yLM166)	*TAC1InteHF-R693K*$_{OE}$	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::***P_{ACT1}-6HIS3FLAG-TAC1-1-R693K/***URA3*	This study
yLM541	DSY2906 (yLM166)	*TAC1InteHF-N972D*$_{OE}$	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::***P_{ACT1}-6HIS3FLAG-TAC1-1-N972D***/URA3*	This study
yLM542	DSY2906 (yLM166)	*pSFS2-MED3KO*	***tac1-1Δ::hisG/ tac1-2Δ::hisG med3Δ::FRT****/MED3*	This study
yLM543	yLM542	*pSFS2-MED3KO*	***tac1-1Δ::hisG/ tac1-2Δ::hisG med3Δ::FRT/med3Δ::FRT***	This study
yLM544	DSY2906 (yLM166)	*pSFS2- SSN3KO*	*tac1-1Δ::hisG/ tac1-2Δ::hisG* ***ssn3Δ::FRT****/SSN3*	This study
yLM545	yLM544	*pSFS2- SSN3KO*	***tac1-1Δ::hisG/ tac1-2Δ::hisG ssn3Δ::FRT/ssn3Δ::FRT***	This study
yLM546	yLM485	*pSFS2-MED3KO*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::***P_{TAC1}-6HIS3FLAG-TAC1-1***/URA3* ***med3Δ::FRT****/MED3*	This study
yLM547	yLM546	*pSFS2-MED3KO*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::***P_{TAC1}-6HIS3FLAG-TAC1-1***/URA3* ***med3Δ::FRT/med3Δ::FRT***	This study
yLM548	yLM534	*pSFS2-MED3KO*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::***P_{TAC1}-6HIS3FLAG-TAC1-1-N972D***/URA3* ***med3Δ::FRT****/MED3*	This study
yLM549	yLM548	*pSFS2-MED3KO*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::***P_{TAC1}-6HIS3FLAG-TAC1-1-N972D***/URA3* ***med3Δ::FRT/med3Δ::FRT***	This study
yLM550	yLM543	*TAC1InteHF-R693K*	*tac1-1Δ::hisG/ tac1-2Δ::hisG* ***med3Δ::FRT/med3Δ::FRT*** *LEU2::***P_{TAC1}-6HIS3FLAG-TAC1-1-R693K***/URA3*	This study
yLM551	yLM543	*TAC1InteHF-Δ962-969*	*tac1-1Δ::hisG/ tac1-2Δ::hisG* ***med3Δ::FRT/med3Δ::FRT***	This study

			LEU2:: ***P_{TAC1}-6HIS3FLAG-TAC1-1-Δ962-969****/URA3*	
yLM552	yLM545	*TAC1InteHF-WT*	*tac1-1Δ::hisG/ tac1-2Δ::hisG* ***ssn3Δ::FRT/ssn3Δ::FRT*** *LEU2::* ***P_{TAC1}-6HIS3FLAG-TAC1-1****/URA3*	This study
yLM553	yLM545	*TAC1InteHF-R693K*	*tac1-1Δ::hisG/ tac1-2Δ::hisG* ***ssn3Δ::FRT/ssn3Δ::FRT*** *LEU2::* ***P_{TAC1}-6HIS3FLAG-TAC1-1-R693K****/URA3*	This study
yLM554	yLM545	*TAC1InteHF-Δ962-969*	*tac1-1Δ::hisG/ tac1-2Δ::hisG* ***ssn3Δ::FRT/ssn3Δ::FRT*** *LEU2::* ***P_{TAC1}-6HIS3FLAG-TAC1-1-Δ962-969****/URA3*	This study
yLM555	yLM534	*pSFS2- SSN3KO*	*tac1-1Δ::hisG/ tac1-2Δ::hisG* *LEU2:* ***:P_{TAC1}-6HIS3FLAG-TAC1-1-N972D****/URA3* ***ssn3Δ::FRT****/SSN3*	This study
yLM556	yLM555	*pSFS2- SSN3KO*	*tac1-1Δ::hisG/ tac1-2Δ::hisG* *LEU2::* ***P_{TAC1}-6HIS3FLAG-TAC1-1-N972D****/URA3* ***ssn3Δ::FRT/ssn3Δ::FRT***	This study
yLM557	yLM504		*tac1-1Δ::hisG/ tac1-2Δ::hisG* *LEU2::* ***TAC1-1-ΔM677****/URA3* ***med3Δ::FRT/med3Δ::FRT*** *CDR1::* ***CDR1-3HA****/CDR1*	This study
SCMRR1M4A (yLM468)	-		*mrr1Δ::FRT/mrr1Δ::FRT*	(7)
yLM558	SCMRR1M4A (yLM468)	*P_{MRR1}-HF-MD-TAC1^{WT}*	*mrr1Δ::FRT/mrr1Δ::* ***P_{MRR1}-6HIS3FLAG-MRR1DBD(aa1-123)-TAC1^{ΔDBD}(aa130-981)***	This study
yLM559	DSY2906 (yLM166)		***tac1-1Δ::hisG/ tac1-2Δ::hisG*** ***MED17-3HA-SAT1****/MED17*	This study
yLM560	DSY2937-35 (yLM167)		*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::* ***TAC1-1****/URA3* ***MED8-3HA-SAT1****/MED8*	This study
yLM482	DSY2937-35 (yLM167)		*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::* ***TAC1-1****/URA3* ***MED17-3HA-SAT1****/MED17*	This study #
yLM483	yLM232		*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::* ***TAC1-1****/URA3* ***med3Δ::FRT/ med3Δ::FRT*** ***MED17-3HA-SAT1****/MED17*	This study #
yLM561	ACY13 (yLM169)		*tac1-1Δ::hisG/ tac1-2Δ::hisG* *LEU2::* ***TAC1-1-A736V****/URA3* ***MED17-3HA-SAT1/****MED17*	This study
yLM562	yLM234		*tac1-1Δ::hisG/ tac1-2Δ::hisG* *LEU2::* ***TAC1-1-A736V****/URA3* ***med3Δ::FRT/ med3Δ::FRT MED17-3HA-SAT1****/MED17*	This study
yLM563	yLM493		*tac1-1Δ::hisG/ tac1-2Δ::hisG* *LEU2::* ***TAC1-1-N972D****/URA3* ***MED17-3HA-SAT1****/MED17*	This study

yLM564	yLM495		*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::***TAC1-1-N972D***/URA3* ***med3Δ::FRT/med3Δ::FRT*** ***MED17-3HA-SAT1****/MED17*	This study
yLM565	yLM496		*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::***TAC1-1-N977D***/URA3* ***MED17-3HA-SAT1****/MED17*	This study
yLM566	yLM498		*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::***TAC1-1-N977D***/URA3* ***med3Δ::FRT/med3Δ::FRT*** ***MED17-3HA-SAT1****/MED17*	This study
SSN3-3HA/ SSN3-3HA (yLM481)	BWP17		*ura3Δ::λimm434/ura3Δ::λimm434 his1Δ::hisG/his1Δ::hisG arg4Δ::hisG/arg4Δ::hisG* ***SSN3::SSN3-3HA-HIS1/ SSN3::SSN3-3HA-SAT1***	(8)
cRC106	-		*ura3Δ::λimm*^{434}*/ura3Δ::λimm*^{434} *ade2::hisG/ade2::hisG::[pOPlacZ]*	(9)
yLM567	cRC106	CIp-LexA	*ura3Δ::λimm*^{434}*/ura3Δ::λimm*^{434} *ade2::hisG/ade2::hisG::[pOPlacZ] RPS10/rps10Δ::[***LexA***]/URA3*	This study
yLM568	cRC106	CIp-LexA-Tac1$^{130-981}$ WT	*ura3Δ::λimm*^{434}*/ura3Δ::λimm*^{434} *ade2::hisG/ade2::hisG::[pOPlacZ] RPS10/rps10Δ::* ***[LexA-TAC1***$^{130-981}$ ***WT]****/URA3*	This study
yLM569	cRC106	CIp-LexA-Tac1$^{130-981}$ T225A	*ura3Δ::λimm*^{434}*/ura3Δ::λimm*^{434} *ade2::hisG/ade2::hisG::[pOPlacZ] RPS10/rps10Δ::* ***[LexA-TAC1***$^{130-981}$ ***T225A]****/URA3*	This study
yLM570	cRC106	CIp-LexA-Tac1$^{130-981}$ E461K	*ura3Δ::λimm*^{434}*/ura3Δ::λimm*^{434} *ade2::hisG/ade2::hisG::[pOPlacZ] RPS10/rps10Δ::* ***[LexA-TAC1***$^{130-981}$ ***E461K]****/URA3*	This study
yLM571	cRC106	CIp-LexA-Tac1$^{130-981}$ ΔM677	*ura3Δ::λimm*^{434}*/ura3Δ::λimm*^{434} *ade2::hisG/ade2::hisG::[pOPlacZ] RPS10/rps10Δ::* ***[LexA-TAC1***$^{130-981}$ ***ΔM677]****/URA3*	This study
yLM572	cRC106	CIp-LexA-Tac1$^{130-981}$ A736V	*ura3Δ::λimm*^{434}*/ura3Δ::λimm*^{434} *ade2::hisG/ade2::hisG::[pOPlacZ] RPS10/rps10Δ::* ***[LexA-TAC1***$^{130-981}$ ***A736V]****/URA3*	This study
yLM573	cRC106	CIp-LexA-Tac1$^{130-981}$ N972D	*ura3Δ::λimm*^{434}*/ura3Δ::λimm*^{434} *ade2::hisG/ade2::hisG::[pOPlacZ] RPS10/rps10Δ::* ***[LexA-TAC1***$^{130-981}$ ***N972D]****/URA3*	This study
yLM574	cRC106	CIp-LexA-Tac1$^{130-981}$ Δ962-969	*ura3Δ::λimm*^{434}*/ura3Δ::λimm*^{434} *ade2::hisG/ade2::hisG::[pOPlacZ] RPS10/rps10Δ::* ***[LexA-TAC1***$^{130-981}$ ***Δ962-969]****/URA3*	This study
yLM575	cRC106	CIp-LexA-Tac1$^{130-981}$ N977D	*ura3Δ::λimm*^{434}*/ura3Δ::λimm*^{434} *ade2::hisG/ade2::hisG::[pOPlacZ] RPS10/rps10Δ::* ***[LexA-TAC1***$^{130-981}$ ***N977D]****/URA3*	This study
yLM576	cRC106	CIp-LexA-	*ura3Δ::λimm*^{434}*/ura3Δ::λimm*^{434}	This study

		Tac1$^{130-981}$ G980E	*ade2::hisG/ade2::hisG::[pOPlacZ] RPS10/rps10Δ:: **[LexA-TAC1$^{130-981}$ G980E]**/URA3*	
yLM577	cRC106	CIp-LexA-Tac1$^{130-981}$ G980W	*ura3Δ::λimm^{434}/ura3Δ::λimm^{434} ade2::hisG/ade2::hisG::[pOPlacZ] RPS10/rps10Δ:: **[LexA-TAC1$^{130-981}$ G980W]**/URA3*	This study
yLM578	cRC106	CIp-LexA-Tac1$^{130-931}$ WT	*ura3Δ::λimm^{434}/ura3Δ::λimm^{434} ade2::hisG/ade2::hisG::[pOPlacZ] RPS10/rps10Δ:: **[LexA-TAC1$^{130-931}$]**/URA3*	This study
yLM579	cRC106	CIp-LexA-Tac1$^{856-981}$ WT	*ura3Δ::λimm^{434}/ura3Δ::λimm^{434} ade2::hisG/ade2::hisG::[pOPlacZ] RPS10/rps10Δ:: **[LexA-TAC1$^{856-981}$]**/URA3*	This study
yLM580	cRC106	CIp-LexA-Tac1$^{932-981}$ WT	*ura3Δ::λimm^{434}/ura3Δ::λimm^{434} ade2::hisG/ade2::hisG::[pOPlacZ] RPS10/rps10Δ:: **[LexA-TAC1$^{932-981}$]**/URA3*	This study
yLM581	cRC106	CIp-LexA-Tac1$^{856-981}$ N972D	*ura3Δ::λimm^{434}/ura3Δ::λimm^{434} ade2::hisG/ade2::hisG::[pOPlacZ] RPS10/rps10Δ:: **[LexA-TAC1$^{856-981}$N972D]**/URA3*	This study
yLM582	cRC106	CIp-LexA-Tac1$^{856-981}$ Δ962-969	*ura3Δ::λimm^{434}/ura3Δ::λimm^{434} ade2::hisG/ade2::hisG::[pOPlacZ] RPS10/rps10Δ:: **[LexA-TAC1$^{856-981}$Δ962-969]**/URA3*	This study
yLM583	cRC106	CIp-LexA-Tac1$^{856-981}$ N977D	*ura3Δ::λimm^{434}/ura3Δ::λimm^{434} ade2::hisG/ade2::hisG::[pOPlacZ] RPS10/rps10Δ:: **[LexA-TAC1$^{856-981}$N977D]**/URA3*	This study
yLM584	cRC106	CIp-LexA-Tac1$^{856-981}$ G980E	*ura3Δ::λimm^{434}/ura3Δ::λimm^{434} ade2::hisG/ade2::hisG::[pOPlacZ] RPS10/rps10Δ:: **[LexA-TAC1$^{856-981}$G980E]**/URA3*	This study
yLM585	cRC106	CIp-LexA-Tac1$^{856-981}$ G980W	*ura3Δ::λimm^{434}/ura3Δ::λimm^{434} ade2::hisG/ade2::hisG::[pOPlacZ] RPS10/rps10Δ:: **[LexA-TAC1$^{856-981}$G980W]**/URA3*	This study
yLM586	cRC106	*pSFS2-MED3KO*	*ura3Δ::λimm^{434}/ura3Δ::λimm^{434} ade2::hisG/ade2::hisG::[pOPlacZ] **med3Δ::FRT**/MED3*	This study
yLM587	yLM586	*pSFS2-MED3KO*	*ura3Δ::λimm^{434}/ura3Δ::λimm^{434} ade2::hisG/ade2::hisG::[pOPlacZ] **med3Δ::FRT/med3Δ::FRT***	This study
yLM588	yLM587	CIp-LexA	*ura3Δ::λimm^{434}/ura3Δ::λimm^{434} ade2::hisG/ade2::hisG::[pOPlacZ] **med3Δ::FRT/med3Δ::FRT** RPS10/rps10Δ::**[LexA]**/URA3*	This study
yLM589	yLM587	CIp-LexA-Tac1$^{130-981}$ WT	*ura3Δ::λimm^{434}/ura3Δ::λimm^{434} ade2::hisG/ade2::hisG::[pOPlacZ] **med3Δ::FRT/med3Δ::FRT** RPS10/rps10Δ:: **[LexA-TAC1$^{130-981}$WT]**/URA3*	This study
yLM590	yLM587	CIp-LexA-	*ura3Δ::λimm^{434}/ura3Δ::λimm^{434}*	This study

		Tac1$^{130-981}$ A736V	*ade2::hisG/ade2::hisG::[pOPlacZ] **med3Δ::FRT/med3Δ::FRT** RPS10/rps10Δ:: [**LexA-TAC1$^{130-981}$A736V**]/URA3*	
yLM591	yLM587	CIp-LexA-Tac1$^{130-981}$ N977D	*ura3Δ::λimm^{434}/ura3Δ::λimm^{434} ade2::hisG/ade2::hisG::[pOPlacZ] **med3Δ::FRT/med3Δ::FRT** RPS10/rps10Δ:: [**LexA-TAC1$^{130-981}$N977D**]/URA3*	This study
yLM592	yLM587	CIp-LexA-Tac1$^{130-981}$ G980E	*ura3Δ::λimm^{434}/ura3Δ::λimm^{434} ade2::hisG/ade2::hisG::[pOPlacZ] **med3Δ::FRT/med3Δ::FRT** RPS10/rps10Δ:: [**LexA-TAC1$^{130-981}$G980E**]/URA3*	This study
yLM593	yLM587	CIp-LexA-Tac1$^{856-981}$ WT	*ura3Δ::λimm^{434}/ura3Δ::λimm^{434} ade2::hisG/ade2::hisG::[pOPlacZ] med3Δ::FRT/med3Δ::FRT RPS10/rps10Δ:: [**LexA-TAC1$^{856-981}$**]/URA3*	This study
yLM594	yLM587	CIp-LexA-Tac1$^{932-981}$ WT	*ura3Δ::λimm^{434}/ura3Δ::λimm^{434} ade2::hisG/ade2::hisG::[pOPlacZ] med3Δ::FRT/med3Δ::FRT RPS10/rps10Δ:: [**LexA-TAC1$^{932-981}$**]/URA3*	This study
yLM595	yLM543	*TAC1InteHF-N972D$_{OE}$*	***tac1-1Δ::hisG/ tac1-2Δ::hisG med3Δ::FRT/med3Δ::FRT*** *LEU2::**$P_{\underline{ACT1}}$-6HIS3FLAG-TAC1-1-N972D/**URA3*	This study
BWP17			*ura3Δ::λimm434/ura3Δ::λimm434 his1Δ::hisG/his1Δ::hisG arg4Δ::hisG/arg4Δ::hisG*	(10)
yLM265	BWP17		***ssn3Δ/ssn3Δ***	This study
yLM279	yLM265		***ssn3Δ/ssn3::SSN3***^{WT}	This study
yLM276	yLM265		***ssn3Δ/ssn3::SSN3***^{D325A}	This study
yLM596	yLM279	*TAC1InteHF-WT$_{OE}$*	***ssn3Δ/ssn3::SSN3***^{WT} *LEU2::**$P_{\underline{ACT1}}$-6HIS3FLAG-TAC1-1***	This study
yLM660	yLM276	*TAC1InteHF-WT$_{OE}$*	***ssn3Δ/ssn3::SSN3***^{D325A} *LEU2::**$P_{\underline{ACT1}}$-6HIS3FLAG-TAC1-1***	This study
yLM597	yLM485		*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**P_{TAC1}-6HIS3FLAG-TAC1-1**/URA3 **MED17-3HA-SAT1**/MED17*	This study
yLM598	yLM539		*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**P_{TAC1}-6HIS3FLAG-TAC1-1-ΔTAD(aa1-845)** /URA3 **MED17-3HA-SAT1**/MED17*	This study
yLM599	yLM503	*pSFS2-CDR2KO* **(two rounds)**	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-ΔM677**/URA3 **med3Δ::FRT**/MED3 **cdr2Δ::FRT/ cdr2Δ::FRT***	This study
yLM600	yLM599	*pSFS2-MED3KO*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-ΔM677** /URA3 **med3Δ::FRT/med3Δ::FRT cdr2Δ::FRT/cdr2Δ::FRT***	This study

yLM471	DSY2937-35 (yLM167)	*pSFS2- SNF2KO*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1**/URA3 **snf2Δ::FRT**/ SNF2*	This study #
yLM472	yLM471	*pSFS2- SNF2KO*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1**/URA3 **snf2Δ::FRT**/ **snf2Δ::FRT***	This study #
yLM473	ACY67 (yLM168)	*pSFS2- SNF2KO*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-T225A**/URA3 **snf2Δ::FRT**/SNF2*	This study #
yLM474	yLM473	*pSFS2- SNF2KO*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-T225A**/URA3 **snf2Δ::FRT**/ **snf2Δ::FRT***	This study #
yLM475	ACY13 (yLM169)	*pSFS2- SNF2KO*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-A736V**/URA3 **snf2Δ::FRT**/SNF2*	This study #
yLM476	yLM475	*pSFS2- SNF2KO*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-G980E**/URA3 **snf2Δ::FRT**/ **snf2Δ::FRT***	This study #
yLM477	ACY71 (yLM170)	*pSFS2- SNF2KO*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-G980E**/URA3 **snf2Δ::FRT**/SNF2*	This study #
yLM478	yLM477	*pSFS2- SNF2KO*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**TAC1-1-G980E**/URA3 **snf2Δ::FRT**/ **snf2Δ::FRT***	This study #
yLM601	DSY2906 (yLM166)	*TAC1Inte HF-E461K*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**P_{TAC1}-6HIS3FLAG-TAC1-1- E461K**/URA3*	This study
yLM602	DSY2906 (yLM166)	*TAC1Inte R693K*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**P_{TAC1}-TAC1-1-R693K**/URA3*	This study
yLM603	DSY2906 (yLM166)	*TAC1InteHF-E461KΔTAD*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**P_{TAC1}-6HIS3FLAG-TAC1-1-E461K-ΔTAD(aa1-845)**/URA3*	This study
yLM604	DSY2906 (yLM166)	*TAC1InteHF-ΔMM677ΔTAD*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**P_{TAC1}-6HIS3FLAG-TAC1-1-ΔM677-ΔTAD(aa1-845)**/URA3*	This study
yLM605	DSY2906 (yLM166)	*TAC1InteHF-R693KΔTAD*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**P_{TAC1}-6HIS3FLAG-TAC1-1-R693K-ΔTAD(aa1-845)**/URA3*	This study
yLM606	DSY2906 (yLM166)	*TAC1InteHF-A736VΔTAD*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**P_{TAC1}-6HIS3FLAG-TAC1-1-A736V-ΔTAD(aa1-845)**/URA3*	This study
yLM607	DSY2906 (yLM166)	*TAC1Inte E461KΔTAD*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**P_{TAC1}-TAC1-1-E461K-ΔTAD (aa1-845)**/URA3*	This study
yLM608	DSY2906 (yLM166)	*TAC1Inte ΔM677ΔTAD*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**P_{TAC1}-TAC1-1-ΔM677-ΔTAD (aa1-845)**/URA3*	This study
yLM609	DSY2906 (yLM166)	*TAC1Inte R693KΔTAD*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::**P_{TAC1}-TAC1-1-R693K-ΔTAD (aa1-845)**/URA3*	This study

yLM610	DSY2906 (yLM166)	*TAC1Inte A736VΔTAD*	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::*P_{TAC1}***-TAC1-1-A736V-ΔTAD (aa1-845)****/URA3*	This study
yLM611	DSY2937-35 (yLM167)	*pSFS2-CDR1KO;* Transient Cas9 system (11)	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::*P_{TAC1}***-TAC1-1****/URA3* ***cdr1Δ::FRT/cdr1Δ::FRT***	This study
yLM612	ACY13 (yLM169)	*pSFS2-CDR1KO;* Transient Cas9 system	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::*P_{TAC1}***-TAC1-1-A736V****/URA3* ***cdr1Δ::FRT/cdr1Δ::FRT***	This study
yLM613	yLM493	*pSFS2-CDR1KO;* Transient Cas9 system	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::*P_{TAC1}***-TAC1-1-N972D****/URA3* ***cdr1Δ::FRT/cdr1Δ::FRT***	This study
yLM614	yLM496	*pSFS2-CDR1KO;* Transient Cas9 system	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::*P_{TAC1}***-TAC1-1-N977D****/URA3* ***cdr1Δ::FRT/ cdr1Δ::FRT***	This study
yLM615	yLM234	*pSFS2-CDR1KO;* Transient Cas9 system	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::*P_{TAC1}***-TAC1-1-A736V****/URA3* ***med3Δ::FRT/med3Δ::FRT cdr1Δ::FRT/cdr1Δ::FRT***	This study
yLM616	yLM495	*pSFS2-CDR1KO;* Transient Cas9 system	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::*P_{TAC1}***-TAC1-1-N972D****/URA3* ***med3Δ::FRT/med3Δ::FRT cdr1Δ::FRT/cdr1Δ::FRT***	This study
yLM617	yLM498	*pSFS2-CDR1KO;* Transient Cas9 system	*tac1-1Δ::hisG/ tac1-2Δ::hisG LEU2::*P_{TAC1}***-TAC1-1-N977D****/URA3* ***med3Δ::FRT/med3Δ::FRT cdr1Δ::FRT/cdr1Δ::FRT***	This study

These strains were also used in a parallel study.

* yLM536 was found with ectopically high expression level of 6His3Flag-Tac1^{N977D}, and used for affinity purification of the 6His3Flag-Tac1^{N977D} sample analyzed in **Fig. 8C**.

Table S5 Plasmids used in this study

Plasmid ^{a}	Description	Checking Primers	Ref.
pDS1097	Vector for integrating *TAC1* promoter driven ***TAC1-1*** (wild type allele referred as *TAC1*^{WT} in this study) with *URA3* marker to *LEU2* locus		(1)
pAC153	Vector for integrating *TAC1* promoter driven ***TAC1***^{T225A} with *URA3* marker to *LEU2* locus		(3)
pAC97	Vector for integrating *TAC1* promoter driven ***TAC1***^{A736V} with *URA3* marker to *LEU2* locus		(3)
pAC157	Vector for integrating *TAC1* promoter driven ***TAC1***^{G980E} with *URA3* marker to *LEU2* locus		(3)
TAC1InteE461K	Vector for integrating *TAC1* promoter driven ***TAC1***^{E461K} with *URA3* marker to *LEU2* locus	ZL536/ZL537 ZL538/ZL539	This study
TAC1InteΔM677	Vector for integrating *TAC1* promoter driven ***TAC1***$^{\Delta M677}$ with *URA3* marker to *LEU2* locus	ZL536/ZL537 ZL538/ZL539	This study
TAC1InteN972D	Vector for integrating *TAC1* promoter driven ***TAC1***^{N972D} with *URA3* marker to *LEU2* locus	ZL536/ZL537 ZL538/ZL539	This study
TAC1InteN977D	Vector for integrating *TAC1* promoter driven ***TAC1***^{N977D} with *URA3* marker to *LEU2* locus	ZL536/ZL537 ZL538/ZL539	This study
TAC1InteΔ962-969	Vector for integrating *TAC1* promoter driven ***TAC1***$^{\Delta 962\text{-}969}$ with *URA3* marker to *LEU2* locus	ZL536/ZL537 ZL538/ZL539	This study
TAC1InteR693K	Vector for integrating *TAC1* promoter driven ***TAC1***^{R693K} with *URA3* marker to *LEU2* locus	ZL536/ZL537 ZL538/ZL539	This study
TAC1InteG980W	Vector for integrating *TAC1* promoter driven ***TAC1***^{G980W} with *URA3* marker to *LEU2* locus	ZL536/ZL537 ZL538/ZL539	This study
TAC1InteHF-WT	Vector for integrating *TAC1* promoter driven ***6HIS3FLAG*** tagged ***TAC1***^{WT} with *URA3* marker to *LEU2* locus	ZL536/ZL537 ZL538/ZL539	This study
TAC1InteHF-A736V	Vector for integrating *TAC1* promoter driven ***6HIS3FLAG*** tagged ***TAC1***^{A736V} with *URA3* marker to *LEU2* locus	ZL536/ZL537 ZL538/ZL539	This study
TAC1InteHF-R693K	Vector for integrating *TAC1* promoter driven ***6HIS3FLAG*** tagged ***TAC1***^{R693K} with *URA3* marker to *LEU2* locus	ZL536/ZL537 ZL538/ZL539	This study
TAC1InteHF-ΔM677	Vector for integrating *TAC1* promoter driven ***6HIS3FLAG*** tagged ***TAC1***$^{\Delta M677}$ with *URA3* marker to *LEU2* locus	ZL536/ZL537 ZL538/ZL539	This study
TAC1InteHF-N972D	Vector for integrating *TAC1* promoter driven ***6HIS3FLAG*** tagged ***TAC1***^{N972D} with *URA3* marker to *LEU2* locus	ZL536/ZL537 ZL538/ZL539	This study
TAC1InteHF-Δ962-969	Vector for integrating *TAC1* promoter driven ***6HIS3FLAG*** tagged ***TAC1***$^{\Delta 962\text{-}969}$ with *URA3* marker to *LEU2* locus	ZL536/ZL537 ZL538/ZL539	This study
TAC1InteHF-N977D	Vector for integrating *TAC1* promoter driven ***6HIS3FLAG*** tagged ***TAC1***^{N977D} with *URA3* marker to *LEU2* locus	ZL536/ZL537 ZL538/ZL539	This study
TAC1InteHF-C43Y	Vector for integrating *TAC1* promoter driven ***6HIS3FLAG*** tagged ***TAC1***^{C43Y} with *URA3* marker to *LEU2* locus	ZL536/ZL537 ZL538/ZL539	This study

TAC1InteHF-R693K/C43Y	Vector for integrating *TAC1* promoter driven ***6HIS3FLAG*** tagged *TAC1*$^{R693K/C43Y}$ with *URA3* marker to *LEU2* locus	ZL536/ZL537 ZL538/ZL539	This study
TAC1InteHF-TAC1ΔTAD	Vector for integrating *TAC1* promoter driven ***6HIS3FLAG*** tagged ***TAC1***$^{1\text{-}845}$***(ΔTAD)*** with *URA3* marker to *LEU2* locus	ZL536/ZL537 ZL538/ZL539	This study
TAC1InteHF-WT$_{OE}$	Vector for integrating ***ACT1*** promoter driven ***6HIS3FLAG*** tagged ***TAC1***^{WT} with *URA3* marker to *LEU2* locus	ZL536/ZL537 ZL538/ZL539	This study
TAC1InteHF-R693K$_{OE}$	Vector for integrating ***ACT1*** promoter driven ***6HIS3FLAG*** tagged ***TAC1***^{R693K} with *URA3* marker to *LEU2* locus	ZL536/ZL537 ZL538/ZL539	This study
TAC1InteHF-N972D$_{OE}$	Vector for integrating ***ACT1*** promoter driven ***6HIS3FLAG*** tagged ***TAC1***^{N972D} with *URA3* marker to *LEU2* locus	ZL536/ZL537 ZL538/ZL539	This study
TAC1InteHF-E461K	Vector for integrating *TAC1* promoter driven ***6HIS3FLAG*** tagged ***TAC1***^{E461K} with *URA3* marker to *LEU2* locus	ZL536/ZL537 ZL538/ZL539	This study
TAC1InteR693K	Vector for integrating *TAC1* promoter driven ***TAC1***^{R693K} with *URA3* marker to *LEU2* locus	ZL536/ZL537 ZL538/ZL539	This study
TAC1InteHF-E461KΔTAD	Vector for integrating *TAC1* promoter driven ***6HIS3FLAG*** tagged ***TAC1***^{E461K}***ΔTAD*** with *URA3* marker to *LEU2* locus	ZL536/ZL537 ZL538/ZL539	This study
TAC1InteHF-ΔM677ΔTAD	Vector for integrating *TAC1* promoter driven ***6HIS3FLAG*** tagged ***TAC1***$^{\Delta M677}$***ΔTAD*** with *URA3* marker to *LEU2* locus	ZL536/ZL537 ZL538/ZL539	This study
TAC1InteHF-R693KΔTAD	Vector for integrating *TAC1* promoter driven ***6HIS3FLAG*** tagged ***TAC1***^{R693K}***ΔTAD*** with *URA3* marker to *LEU2* locus	ZL536/ZL537 ZL538/ZL539	This study
TAC1InteHF-A736VΔTAD	Vector for integrating *TAC1* promoter driven ***6HIS3FLAG*** tagged ***TAC1***^{A736V}***ΔTAD*** with *URA3* marker to *LEU2* locus	ZL536/ZL537 ZL538/ZL539	This study
TAC1InteE461KΔTAD	Vector for integrating *TAC1* promoter driven ***TAC1***^{E461K}***ΔTAD*** with *URA3* marker to *LEU2* locus	ZL536/ZL537 ZL538/ZL539	This study
TAC1InteΔM677ΔTAD	Vector for integrating *TAC1* promoter driven ***TAC1***$^{\Delta M677}$***ΔTAD*** with *URA3* marker to *LEU2* locus	ZL536/ZL537 ZL538/ZL539	This study
TAC1InteR693KΔTAD	Vector for integrating *TAC1* promoter driven ***TAC1***^{R693K}***ΔTAD*** with *URA3* marker to *LEU2* locus	ZL536/ZL537 ZL538/ZL539	This study
TAC1InteA736VΔTAD	Vector for integrating *TAC1* promoter driven ***TAC1***^{A736V}***ΔTAD*** with *URA3* marker to *LEU2* locus	ZL536/ZL537 ZL538/ZL539	This study
pSFS2-MED3KO [#][b]	*SAT1* flipper construct for deleting *C. albicans* ***MED3*** ORF	*AZ146/Kpp063* *Kpp062/AZ147'* **ZL257/AZ147'**	This study
pSFS2-SSN3KO [#][b]	*SAT1* flipper construct for deleting *C. albicans* ***SSN3*** ORF	*AZ357/Kpp063* *Kpp062/AZ358* **ZL177/ZL178**	This study
pSFS2-MED15KO [b]	*SAT1* flipper construct for deleting *C. albicans* ***MED15*** ORF	*ZL082/Kpp063* *Kpp062/ZL074* **ZL085/ZL086**	This study
pSFS2-CDR2KO [b]	*SAT1* flipper construct for deleting *C. albicans* ***CDR2*** ORF	*ZL528/Kpp063* *Kpp062/ZL808* **ZL542/ZL543**	This study
pSFS2-SNF2KO [#][b]	*SAT1* flipper construct for deleting *C. albicans* ***SNF2*** ORF	*ZL593/Kpp063*	This study

		Kpp062/ZL594 **ZL621/ZL622** **ZL623/ZL594**	
pSFS2-CDR1KO[c]	*SAT1* flipper construct for deleting *C. albicans* ***CDR1*** ORF		This study
CIp-LexA	Vector for expressing **LexA** protein in *C. albicans LacZ* reporter strains cRC106 and yLM587; targeting *RPS10* locus with *URA3* marker	ZL174/ZL093 ZL094/ZL173	(9)
CIp-LexA-Tac1$^{130-981}$ WT	Vector for expressing **LexA-Tac1$^{130-981}$WT** protein in *C. albicans LacZ* reporter strains cRC106 and yLM587; targeting *RPS10* locus with *URA3* marker	ZL174/ZL093 ZL094/ZL485	This study
CIp-LexA-Tac1$^{130-981}$ T225A	Vector for expressing **LexA-Tac1$^{130-981}$T225A** protein in *C. albicans LacZ* reporter strain cRC106; targeting *RPS10* locus with *URA3* marker	ZL174/ZL093 ZL094/ZL485	This study
CIp-LexA-Tac1$^{130-981}$ E461K	Vector for expressing **LexA-Tac1$^{130-981}$E461K** protein in *C. albicans LacZ* reporter strain cRC106; targeting *RPS10* locus with *URA3* marker	ZL174/ZL093 ZL094/ZL485	This study
CIp-LexA-Tac1$^{130-981}$ ΔM677	Vector for expressing **LexA-Tac1$^{130-981}$ΔM677** protein in *C. albicans LacZ* reporter strain cRC106; targeting *RPS10* locus with *URA3* marker	ZL174/ZL093 ZL094/ZL485	This study
CIp-LexA-Tac1$^{130-981}$ A736V	Vector for expressing **LexA-Tac1$^{130-981}$A736V** protein in *C. albicans LacZ* reporter strains cRC106 and yLM587; targeting *RPS10* locus with *URA3* marker	ZL174/ZL093 ZL094/ZL485	This study
CIp-LexA-Tac1$^{130-981}$ N972D	Vector for expressing **LexA-Tac1$^{130-981}$N972D** protein in *C. albicans LacZ* reporter strain cRC106; targeting *RPS10* locus with *URA3* marker	ZL174/ZL093 ZL094/ZL485	This study
CIp-LexA-Tac1$^{130-981}$ Δ962-969	Vector for expressing **LexA-Tac1$^{130-981}$Δ962-969** protein in *C. albicans LacZ* reporter strain cRC106; targeting *RPS10* locus with *URA3* marker	ZL174/ZL093 ZL094/ZL485	This study
CIp-LexA-Tac1$^{130-981}$ N977D	Vector for expressing **LexA-Tac1$^{130-981}$N977D** protein in *C. albicans LacZ* reporter strains cRC106 and yLM587; targeting *RPS10* locus with *URA3* marker	ZL174/ZL093 ZL094/ZL485	This study
CIp-LexA-Tac1$^{130-981}$ G980E	Vector for expressing **LexA-Tac1$^{130-981}$G980E** protein in *C. albicans LacZ* reporter strains cRC106 and yLM587; targeting *RPS10* locus with *URA3* marker	ZL174/ZL093 ZL094/ZL485	This study
CIp-LexA-Tac1$^{130-981}$ G980W	Vector for expressing **LexA-Tac1$^{130-981}$G980W** protein in *C. albicans LacZ* reporter strain cRC106; targeting *RPS10* locus with *URA3* marker	ZL174/ZL093 ZL094/ZL485	This study
CIp-LexA-Tac1$^{130-931}$ WT	Vector for expressing **LexA-Tac1$^{130-931}$WT** protein in *C. albicans LacZ* reporter strain cRC106; targeting *RPS10* locus with *URA3* marker	ZL174/ZL093 ZL094/ZL485	This study
CIp-LexA-Tac1$^{856-981}$ WT	Vector for expressing **LexA-Tac1$^{856-981}$WT** protein in *C. albicans LacZ* reporter strains cRC106 and yLM587; targeting *RPS10* locus with *URA3* marker	ZL174/ZL093 ZL094/ZL485	This study
CIp-LexA-Tac1$^{932-981}$ WT	Vector for expressing **LexA-Tac1$^{932-981}$WT** protein in *C.*	ZL174/ZL093	This study

	albicans LacZ reporter strains cRC106 and yLM587; targeting *RPS10* locus with *URA3* marker	ZL094/ZL560	
CIp-LexA-Tac1$^{856-981}$ N972D	Vector for expressing **LexA-Tac1$^{856-981}$N972D** protein in *C. albicans LacZ* reporter strain cRC106; targeting *RPS10* locus with *URA3* marker	ZL174/ZL093 ZL094/ZL485	This study
CIp-LexA-Tac1$^{856-981}$ Δ962-969	Vector for expressing **LexA-Tac1$^{856-981}$Δ962-969** protein in *C. albicans LacZ* reporter strain cRC106; targeting *RPS10* locus with *URA3* marker	ZL174/ZL093 ZL094/ZL485	This study
CIp-LexA-Tac1$^{856-981}$ N977D	Vector for expressing **LexA-Tac1$^{856-981}$N977D** protein in *C. albicans LacZ* reporter strain cRC106; targeting *RPS10* locus with *URA3* marker	ZL174/ZL093 ZL094/ZL485	This study
CIp-LexA-Tac1$^{856-981}$ G980E	Vector for expressing **LexA-Tac1$^{856-981}$G980E** protein in *C. albicans LacZ* reporter strain cRC106; targeting *RPS10* locus with *URA3* marker	ZL174/ZL093 ZL094/ZL485	This study
CIp-LexA-Tac1$^{856-981}$ G980W	Vector for expressing **LexA-Tac1$^{856-981}$G980W** protein in *C. albicans LacZ* reporter strain cRC106; targeting *RPS10* locus with *URA3* marker	ZL174/ZL093 ZL094/ZL485	This study
pV1093	A tool plasmid for *C. albicans* CRISPR-Cas9 system		(12)

[a] Before transformation into *C. albicans*, vectors for introducing native or tagged *TAC1* variants (the '*TAC1Inte*' plasmids) were linearized by **SalI**; vectors for expressing LexA fusion proteins (the 'CIp-LexA' plasmids) were linearized by **StuI**; *SAT1* flipper cassettes for gene disruption were released from the '*pSFS2*' constructs by **SacI/ApaI** digestion.

[b] When a *pSFS2* construct was used for a conventional two-round gene knock-out, positive PCR amplification by primer pairs in *italics* confirmed its correct integration at one of the two gene loci. Disruption of the remaining allele was identified by loss of specific amplification products by the primer pair(s) in **Bold** in genotyping PCR tests.

[c] Use of *pSFS2-CDR1KO* plasmid as a repairing template in a transient CRISPR-Cas9 system (11) to delete *CDR1* was described in **Supplemental Methods** session in detail.

[#] These DNA constructs are also used in a parallel study.

Table S6 Primers used in this study

Primer name	Primer sequence	Note [a]
AZ146	TGACGAACTTGTTTCCAAAC	
AZ147’	TGGATAAGTGTGATCTATCG	
Kpp062	GTAATGGTACAGATGGTACTAGAC	
Kpp063	CACAGGATGACGCCTAAC	
LM065	GAGAAGAGCTCACTGTCATTATTAGGGAGAG	SacI
LM066	GAGAACCGCGGTTGTGGTTTTGTATATCTTTGT	SacII
LM067	GAGAACTCGAGGGACATAGTTCCTACTGTAC	XhoI
LM068	GAGAAGGGCCCCTTTCTAATTGATGTCGTTTGTC	ApaI
LM069	GAGAAGAGCTCCTCAAAGTCAAACACAATCTTT	SacI
LM070	GAGAACCGCGGCTAAATGAAGCTGAACTATAACT	SacII
LM071	GAGAACTCGAGTGGGTAGATAGATATAGATGTCA	XhoI
LM072	GAGAAGGGCCCTCATAACGATACAATTTGGTGC	ApaI
LM073	GAGAAGAGCTCCCACAATACAACCCTACC	SacI
LM074	GAGAACCGCGGAATAGGCAATCCGGACAC	SacII
LM075	GAGAACTCGAGAGCTGACTTTTAGTAATC	XhoI
LM076	GAGAAGGGCCCTAACGTTTGATATGTGCC	ApaI
AZ357	CAGGAGATAACAATAAGTTTGAG	
AZ358	CAAGTCCTGAACTCATTGATTTTAACC	
ZL082 (TRR05)	GACAATCAAAATTTCTCATATCAAC	
ZL074 (TRR06)	GGAGGTTATGGTTGTTCC	
ZL085	TTACTGTTGTTGTGGGTACTAG	
ZL086	TCCATGGTATGCACTTGC	
ZL177	GGCCATCAATTGCTGCAACAAC	
ZL178	TATTCTCCTCTTGAATGTACAGC	
ZL804	AATAAgagctcAAAGTTACTCACATCATAAGCTG	SacI
ZL805	TGCGAccgcggCGTGTTTGCAGTACTCATATG	SacII
ZL806	CTGGTctcgagGAGTTCCAAAAGGTAATAGAG	XhoI
ZL807	ATGAGgggcccGGTGCTACCAATGTCCCACAC	ApaI
ZL808	TCCTTTGTCTTTAAGAGCAGCC	
ZL536	ATGGTCCAAAAGGTATTGGTGCC	
ZL537	Cttaactatgcggcatcagagc	
ZL538	Gccctggactacattttgtctc	
ZL539	Cagctgtttctatcacggtttcg	
ZL540	ATTCTAAGATGTCGTCGCAAGATG	(13)
ZL541	AGTTCTGGCTAAATTCTGAATGTTTTC	(13)
ZL542	TAGTCCATTCAACGGCAACATT	(13)
ZL543	CACCCAGTATTTGGCATTGAAA	(13)

ZL712	TGGTGATGGTGTTACTCACG	(14)
ZL713	GACAATTTCTCTTTCAGCAC	(14)
ZL544	AACTTCAACAACTCTATCC	
ZL545	GAGGCACTAATGTAATCC	
LM077	gcaaggatccaagaagaagtggataattttgattaac	BamHI (1)
LM078	gcaactcgagagtatattctgttgggaaaggggtgag	XhoI (1)
LM085	attagattcgcccaaaaaattggtcttcataga	
LM086	tctatgaagaccaatttttgggcgaatctaat	
ZL558	ATTTACAGCCGAATTATCAATCAAATAGTC	
ZL559	GACTATTTGATTGATAATTCGGCTGTAAATTTACCCAATTTTTCTTTGACAATAATTTG	
ZL560	CCAATTTTTCTTTGACgATAATTTGGGGATTTAA	
ZL561	TTAAATCCCCAAATTATcGTCAAAGAAAAAATTGG	
ZL564	GATTATTAATCGATATCCATTAATTGCTACCGAAGATTCC	
ZL565	GGAATCTTCGGTAGCAATTAATGGATATCGATTAATAATC	
ZL572	CAATTTAATAATTTACCCgatTTTTTCTTTGACAATAATTTG	
ZL573	CAAATTATTGTCAAAGAAAAAatcGGGTAAATTATTAAATTG	
ZL612	CGAGTAATAAAATTTAaAAATCTTTCATTGGAT	
ZL613	ATCCAATGAAAGATTTtTAAATTTTATTACTCG	
ZL552	AATATCATTCTTACGGTGATCTTTTATTGGTTAGCTAGAGTTCCAAAGGGTAACAGAGAGAAAAAAAATAAGAAAggtcgacggatcccc	
ZL553	CAATAGTCTAAAAACGTCTATTATATTTTAGACGTTTGAGATACCACCATGTCAAAAAACAAACTGTTTAATtcgatgaattcgagctcg	
ZL554	ATGTACAGATGTAATCCATTCAC	
ZL555	CACATGACCACTAACCACCACG	
ZL636	AGCTGGTACCCGTGGTGGTGGTGGTGGTGCATTATTTATGAGAGAAGGAGAAAGGC	KpnI
ZL637	tGTCCATacctccCTGcggtgaCTTGTCATCGTC	
ZL638	ccgCAGggaggtATGGACACTTCACTGTCACTGGGA	
ZL639	TAATggatccAGTCTAATATTTCTTTTGGAC	BamHI
ZL640	GCTGGTACCCGTGGTGGTGGTGGTGGTGCATTTTGAATGATTATATTTTTTTAATATTAATATCG	KpnI
ZL696	GAGTGGCATGTGATAGTTaTCGGAGAAAGAAAATTAAATGC	
ZL697	GCATTTAATTTTCTTTCTCCGAtAACTATCACATGCCACTC	
ZL706	tggtgatttctttgaatttttacg	
ZL707	cgtaaaaattcaaagaaatcaccaAATGACAACAAATCAAGTG	
ZL708	CATCggatccACCAATTACAACTCTTTTTTAACCC	BamHI
ZL648	AACGTTCTACAGCTTGGGTTCAGTGATTTCAATGAAATCGAAGAATGCTTGGATTGGTCGATCCAAAATTTTGTAggtcgacggatcccc	
ZL649	GAACAGTGATGTACAGTGGTTATATTTATACCTGAATGTTATAATACTTTTCGTTAAATACTTGTACATATAtcgatgaattcgagctcg	
ZL650	AACCTCTAATATGTTGGACG	
ZL651	GAGAGATGAAAAGTATTACCG	

LM023	TGAAAATAACTGCTGGTGGTCAAAAAAGTTTGCATCCAAATCAAGTATTGAAATTTATGTGTCAAGGACAGATAggtcgacggatccccg	
LM014	AACACACAGTAATATTACATAAACCACCATCTTGTTCTTCTTCTACTTCATCCCCCCCTCTCCTAAAAATTtcgatgaattcgagctcgt	
KPP017	AAGGATAAAGAATTTGAACG	
KPP018	TATATAGATCAGAAACAACA	
LM21	CTAATTAACGTGTGTGTATGGATC	
ZL514	ATTGACGACGATGATGAC	1-up^{F}
ZL515	ATAAGAAGTTGAGGCGAAG	1-up^{R}
ZL849	ATCCTCGTTACTCAATAAG	1-1^{F}
ZL850	AGACACTAACTCCGTATT	1-1^{R}
ZL851	TGCGTGACCCAAACATAATCT	1-2^{F}
ZL852	TGTGACGAGGTGGCTGAT	1-2^{R}
ZL853	GTAAGAGGAGTAGCAAGTG	1-3^{F}
ZL854	TTAAGCGATTCTGGTAGTTAT	1-3^{R}
ZL518	tttcaacatattagaatcgaatcattacg	1-DRE^{F} (15)
ZL519	gcggctgtgtgtttgtgtg	1-DRE^{R} (15)
ZL528	CATCTTGCGGTTCTAATAG	2-up^{F}
ZL529	CACTCTAATCTGATATGGTTC	2-up^{R}
ZL855	TCAACTGTTAAGTCCGATAA	2-1^{F}
ZL856	TGTAGATTGTCTGAGTCTTG	2-1^{R}
ZL857	GACTCAGACAATCTACAA	2-2^{F}
ZL858	AGTTTGACATCCTTGAAT	2-2^{R}
ZL859	CTGATAATATACCTCTGTCGTAA	2-3^{F}
ZL860	GGTCACATCTTGTCAACA	2-3^{R}
ZL861	TGTGACCAGGTAGTGATAGT	2-4^{F}
ZL862	GCATTGCTGAGAGTGGAA	2-4^{R}
ZL532	aattcaaacacaaacaataaggctgt	2-DRE^{F} (15)
ZL533	gcaatcattgtggtatacatcgga	2-DRE^{R} (15)
ZL488	GGT CCA CGC GTT CCA GCA ACA TCA ACA TCG	MluI
ZL489	GGT CCA CGC GTT GGT GGT TGT GGT AGC AGG AAC	MluI
ZL490	GAA GCT GCA GAC CAA TTA CAA CTC TTT TTT AAC CC	PstI
ZL524	ccgcCTGCAGTTAAATCTCCAAATTATTGTC	PstI
ZL525	ccgcCTGCAGTTAAATCCACAAATTATTGTC	PstI
ZL526	GCGCAAACTCGAgTTAAATCCACAAATTATTGTC	XhoI
ZL527	ccgcCTGCAGTTAAATCCCCAAATTATcGTCAAAGAAAAAATTGG	PstI
ZL173	Gatgaagcaactgtcaaacgc	
ZL174	GGAATGCTTATTTGAAAAAGACTGGC	
ZL093	CTCACGCACGCCCATACTAC	

ZL094	GAGAGAAACTATATTATACAC	
ZL485 (Zinc2-3224)	ATGCTCAGTCACCAAGTTA	(1)
ZL691	ACTAATAAGGAAACTTTGCGG	
ZL692	CGGCATCAAACCGAATTGG	
ZL693	ATTTCACAACACCTGGCTG	
ZL481 (Zinc2-1123)	GATGCCAACGAATTATTGA	(1)
ZL486 (Zinc2-1798c)	ACA TCA ACA ATG CTT CTA C	(1)
ZL670	CCAActcgagTTATTTGGACGTGAATTCCGC	XhoI
ZL671	gggtggatccTTCGGAGCTCAATTTGCGTTTAGCCgaag	BamHI/SacI
ZL672	AGCTGGTACCCGTGGTGGTGGTGGTGGTGcatttttaataaattagattaataattcg	KpnI
ZL673	ttgacatacctccCTGcggtgaCTTGTCATCGTC	
ZL674	ccgCAGggaggtatgtcaattgccaccacc	
ZL690	gttgatgaattctatcgacc	
ZL556	ggtccacgcgttGGTGGAGGTCCAGGTGGAGATCTAGAATCGAGATTGAGTCG	MluI
ZL557	gcGAATTGGGTggCGcGCCCCCCCTCGA	AscI
ZL185	TCCATTACCTGAACACTT	
ZL630	TGTTGGCGCGCCtcaTGAACGACCTGTGCTTTC	AscI
ZL550	TGTTGGTAGAGTGACTTATC	
ZL551	TGTTATTGGAAGATGATGATTG	
ZL578	CAGTGTTATCAGTGAAGG	
ZL579	TGCTCTATGAAGACCAAT	
ZL386	CGGTAAGGTTACTGGTAAG	
ZL387	AATGGCAATCTCAATGGT	
ZL907	gtGGGAGCTCAACGGAAAATTGC	SacI
ZL908	TAAAAccgcggATATCTTAAAGGGTAGATCTCAAC	SacII
ZL909	ATAActcgagCAGTTTGTTTTTTGACATGGTGG	XhoI
ZL910	GTATgggcccTTGCAACGGAAGAGTCGG	ApaI
ZL911	GGGGTAGGGATCGGATAGT	
ZL912	ACAGATGAGAAACACTTTTTCC	
ZL914 (CaCas9/for)	ATCTCATTAGATTTGGAACTTGTGGGTT	(11)
ZL915 (CaCas9/rev)	TTCGAGCGTCCCAAAACCTTCT	(11)
ZL916 (SNR52/F)	AAGAAAGAAAGAAAACCAGGAGTGAA	(11)
ZL917 (sgRNA/R)	ACAAATATTTAAACTCGGGACCTGG	(11)
ZL918	GCGGCCGCAAGTGATTAGACT	(11)

(SNR52/N)		
ZL919 (sgRNA/N)	GCAGCTCAGTGATTAAGAGTAAAGATGG	(11)
ZL926	**ATACAAGTGAAAACATTCAG**CAAATTAAAAATAGTTTACGCAAGTC	
ZL927	**CTGAATGTTTTCACTTGTAT**GTTTTAGAGCTAGAAATAGCAAGTTAAA	
ZL654	GTGCTGAACGTGAATATG	
ZL257	gttggggatccgtGTTGAAGGGCCACCTCCAAG	

[a] The ‘Note’ column denotes the restriction enzyme cutting site(s) added for cloning or the annealing region of a ChIP assay primer (referring to **Fig. 3A**).

Supplemental Methods

Construction of vectors for expression of Tac1 variants from *LEU2* locus

Gain-of-function point mutations were individually introduced into pDS1097 (1) to generate the corresponding '*TAC1Inte'* plasmids listed in **Table S5**. In details, PCR amplicons of ZL481/LM086, ZL481/ZL565, ZL481/ZL573, ZL481/ZL561 ZL481/ZL558 and ZL481/ZL613 from pDS1097, were respectively fused to amplicons of LM085/LM078, ZL564/LM078, ZL572/LM078, ZL560/LM078, ZL559/LM078 and ZL612/LM078 by fusion PCR. The resulting DNA fragments were digested by PstI and XhoI and ligated to pDS1097 vector cut by the same enzymes to generate *TAC1Inte-E461K, -ΔM677, -N972D*, *-N977D*, *-Δ962-969* and *-R693K*, respectively. *TAC1Inte-G980W* was constructed by ligating PstI/XhoI digested ZL481/ZL526 amplicon from pDS1097 to pDS1097 vector digested by the same enzymes.

Construction of vectors for expression of 6His3Flag tagged Tac1 variants from *LEU2* locus

6His3Flag tag coding sequence was first introduced to the 5' end of wild type *TAC1* ORF on pDS1097. Specifically, pDS1097 was used as the template and LM077/ZL636 as the primer pair, *TAC1* promoter (including the translation start codon) was amplified with 6His coding sequence added at 3' end. This fragment was digested by BamHI/KpnI and ligated to *pFA-6HIS3FLAG-SAT1* (6) vector digested by the same enzymes. LM077/ZL637 amplicon from the resulting plasmid, which contains *TAC1* promoter driven entire *6HIS3FLAG* tag was fused to Tac1 (aa1-433) coding sequence amplified from pDS1097 by ZL638/ZL486 through fusion PCR. The product was digested by BamHI/PstI and ligated to pDS1097 cut at the same sites to generate *TAC1InteHF-WT*. After confirmed by DNA sequencing, the BamHI/PstI fragment was re-cleaved from *TAC1InteHF-WT* and sub-cloned into *TAC1Inte-E461K, -ΔM677, -N972D, -N977D***,** *-Δ962-969* and *-R693K* between the same sites, resulting in each corresponding '*TAC1InteHF*' plasmid. To introduce C43Y mutation to Tac1 DNA binding domain, fusion PCR product sealing the amplicon of LM077/ZL697 and amplicon of ZL696/ZL486 both from *TAC1InteHF-WT,* was digested by BamHI/PstI and ligated to T*AC1InteHF-WT and TAC1InteHF-R693K* cut by the same enzymes. *TAC1InteHF-TAC1ΔTAD* was derived from *TAC1InteHF-TAC1* by replacing the sequence between the PstI and XhoI sites by a ZL481/ZL670 amplicon digested by the same enzymes. The same method was used to generate the plasmids for expression of 6His3Flag tagged Tac1^{GOF} TAD truncation mutants (*TAC1InteHF-E461KΔTAD*, *-ΔM677ΔTAD, -R693KΔTAD and -A736VΔTAD*) and their untagged forms (*TAC1InteE461KΔTAD*, *ΔM677ΔTAD, R693KΔTAD and A736VΔTAD*) from the corresponding '*TAC1InteHF'* and '*TAC1Inte*' constructs.

Construction of SAT1 flipper vectors for gene disruption

To generate SAT1 flipper (16) constructs for deleting *MED3*, *SSN3*, *MED15*, *CDR2*, *SNF2* and *CDR1* in *C. albicans*, 5' homologous regions (5' HRs) for each gene were respectively amplified by LM065/LM066, LM069/LM070, LM073/LM074, ZL804/ZL805, ZL589/ZL590 and ZL907/ZL908 from genomic DNA and 3' HRs respectively by LM067/LM068, LM071/LM072, LM075/LM076, ZL806/ZL807, ZL591/ZL592 and ZL909/ZL910. pSFS2 vectors with individual 5' HR inserted between the SacI/SacII sites and the corresponding 3' HR inserted between the XhoI/ApaI sites were named as *pSFS2-MED3KO*, *pSFS2-SSN3KO*, *pSFS2-MED15KO*, *pSFS2-CDR2KO*, *pSFS2-SNF2KO* and *pSFS2-CDR1KO* according to their gene targets.

Construction of vectors for over-expression of 6His3Flag tagged Tac1 variants

Using *C. albicans* genomic DNA as template and ZL639/ZL640 as primers, *ACT1* promoter (including the translation start codon) was amplified with 6His coding sequence added at its 3' end. This fragment was digested by BamHI/KpnI and inserted into *pFA-6HIS3FLAG-SAT1* between the two sites. ZL639/ZL637 amplicon from the resulting plasmid, which contains *ACT1* promoter driven complete 6His3Flag tag sequence, after fused to Tac1 (aa1-433) coding sequence amplified from pDS1097 by ZL638/ZL486, was digested by BamHI/PstI and ligated to pDS1097 cut at the same sites to generate *TAC1InteHF-WT*$_{OE}$. The BamHI/PstI insertion, after confirmed by DNA sequencing, was also sub-cloned into *TAC1InteHF-R693K and TAC1InteHF-N972D* to generate the corresponding over-expression vector *TAC1InteHF-R693K*$_{OE}$ and *TAC1InteHF-N972D*$_{OE}$.

Construction of vectors for expression of LexA fused Tac1 fragments in *LacZ* reporter strains

DNA fragments encoding Tac1 TAD (aa856-981) variants (wild type, *N972D*, *Δ962-969*, *N977D*, *G980E* and *G980W*) were amplified respectively by ZL489/ZL490 from pDS1097, ZL489/ZL490 from *TAC1Inte-N972D,* ZL489/ZL490 from *TAC1Inte-Δ962-969*, ZL489/ZL527 from pDS1097, ZL489/ZL524 from pDS1097 and ZL489/ZL525 from pDS1097, digested by MluI/PstI and inserted into CIp-LexA (9) vector between the same sites. The shorter form of wild type Tac1 TAD (aa932-981) coding sequence amplified by ZL488 and ZL490 from pDS1097 was introduced into CIp-LexA in the same way.

Vectors expressing LexA-Tac1(aa130-981) variants (CIp-LexA-Tac$^{130\text{-}981}$WT, -255A, -E461K, -ΔM677, -A736V, -N972D, -Δ962-969, -N977D, -G980E and -G980W) were constructed by inserting MluI/AscI digested ZL556/ZL557 amplicon respectively from pDS1097, ACY67, *TAC1Inte-E461K*, *TAC1Inte-ΔM677*, pAC97, *TAC1Inte-N972D*, *TAC1Inte-Δ962-969*, *TAC1Inte-N977D*, pAC157 and *TAC1Inte-G980W* into MluI linearized CIp-LexA vector. Correctly oriented insertion was selected by positive amplification of ZL185/ZL486 and negative amplification of ZL185/ZL485. In addition, ZL556/ZL630 amplicon from pDS1097 was inserted into CIp-LexA in the same way to generate CIp-LexA-Tac1$^{130\text{-}931}$WT.

Deletion of *cdr1* by a transient CRISPR-Cas9 system

Deletion of *cdr1* was performed using the system and protocol described in (11) with modifications. A Cas9 cassette was amplified by ZL914/ZL915 from pV1093 (12). A sgRNA cassette was generated by a nest fusion PCR (11), where ZL918/ZL919 was used to seal the two fragments amplified from pV1093 by ZL916/ZL926 and ZL927/ZL917. Choose of the sgRNA sequence was guided by a genome-wide search described in (12). A DNA mixture containing 800 ng of Cas9 cassette, 800 ng of sgRNA cassette and 500 ng of SacI/ApaI digested *pSFS2-CDR1KO* plasmid, which serves as a repairing template, were used to transform *C. albicans* cells by electroporation. Transformants with deletions in both copies of *CDR1* were identified by loss of the ZL540/ZL541 and ZL654/ZL912 amplicons during PCR testing.

References

1. **Coste AT, Karababa M, Ischer F, Bille J, Sanglard D.** 2004. TAC1, transcriptional activator of CDR genes, is a new transcription factor involved in the regulation of Candida albicans ABC transporters CDR1 and CDR2. Eukaryot Cell **3:**1639-1652.
2. **Coste A, Turner V, Ischer F, Morschhauser J, Forche A, Selmecki A, Berman J, Bille J, Sanglard D.** 2006. A mutation in Tac1p, a transcription factor regulating CDR1 and CDR2, is coupled with loss of heterozygosity at chromosome 5 to mediate antifungal resistance in Candida albicans. Genetics **172:**2139-2156.
3. **Coste A, Selmecki A, Forche A, Diogo D, Bougnoux ME, d'Enfert C, Berman J, Sanglard D.** 2007. Genotypic evolution of azole resistance mechanisms in sequential Candida albicans isolates. Eukaryot Cell **6:**1889-1904.
4. **Noble SM, Johnson AD.** 2005. Strains and strategies for large-scale gene deletion studies of the diploid human fungal pathogen Candida albicans. Eukaryot Cell **4:**298-309.
5. **Zhang A, Liu Z, Myers LC.** 2013. Differential regulation of white-opaque switching by individual subunits of Candida albicans mediator. Eukaryot Cell **12:**1293-1304.
6. **Zhang A, Petrov KO, Hyun ER, Liu Z, Gerber SA, Myers LC.** 2012. The Tlo proteins are stoichiometric components of Candida albicans mediator anchored via the Med3 subunit. Eukaryot Cell **11:**874-884.
7. **Morschhauser J, Barker KS, Liu TT, Bla BWJ, Homayouni R, Rogers PD.** 2007. The transcription factor Mrr1p controls expression of the MDR1 efflux pump and mediates multidrug resistance in Candida albicans. PLoS Pathog **3:**e164.
8. **Lindsay AK, Morales DK, Liu Z, Grahl N, Zhang A, Willger SD, Myers LC, Hogan DA.** 2014. Analysis of Candida albicans mutants defective in the Cdk8 module of mediator reveal links between metabolism and biofilm formation. PLoS Genet **10:**e1004567.
9. **Russell CL, Brown AJ.** 2005. Expression of one-hybrid fusions with Staphylococcus aureus lexA in Candida albicans confirms that Nrg1 is a transcriptional repressor and that Gcn4 is a transcriptional activator. Fungal Genet Biol **42:**676-683.
10. **Wilson RB, Davis D, Mitchell AP.** 1999. Rapid hypothesis testing with Candida albicans through gene disruption with short homology regions. J Bacteriol **181:**1868-1874.
11. **Min K, Ichikawa Y, Woolford CA, Mitchell AP.** 2016. Candida albicans Gene Deletion with a Transient CRISPR-Cas9 System. mSphere **1**.
12. **Vyas VK, Barrasa MI, Fink GR.** 2015. A Candida albicans CRISPR system permits genetic engineering of essential genes and gene families. Sci Adv **1:**e1500248.

13. **Liu TT, Znaidi S, Barker KS, Xu L, Homayouni R, Saidane S, Morschhauser J, Nantel A, Raymond M, Rogers PD.** 2007. Genome-wide expression and location analyses of the Candida albicans Tac1p regulon. Eukaryot Cell **6:**2122-2138.
14. **Lu Y, Su C, Liu H.** 2012. A GATA transcription factor recruits Hda1 in response to reduced Tor1 signaling to establish a hyphal chromatin state in Candida albicans. PLoS Pathog **8:**e1002663.
15. **Coste AT, Crittin J, Bauser C, Rohde B, Sanglard D.** 2009. Functional analysis of cis- and trans-acting elements of the Candida albicans CDR2 promoter with a novel promoter reporter system. Eukaryot Cell **8:**1250-1267.
16. **Reuss O, Vik A, Kolter R, Morschhauser J.** 2004. The SAT1 flipper, an optimized tool for gene disruption in Candida albicans. Gene **341:**119-127.